Connection
Paul Bunn to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications Paul Bunn has written about Programmed Cell Death 1 Receptor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.180 |
|
|
|
-
He Y, Liu S, Mattei J, Bunn PA, Zhou C, Chan D. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. Drug Des Devel Ther. 2018; 12:981-986.
Score: 0.135
-
Lin EP, Hsu CY, Chiou JF, Berry L, Horn L, Bunn P, Yang JC, Yang PC, Adjei AA, Shyr Y. Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit. J Thorac Oncol. 2022 12; 17(12):1365-1374.
Score: 0.046